How do you tailor rituximab dosing for mucosal-predominant vs mucocutaneous pemphigus?

No, I do not dose cutaneous vs mucocutaneous patients with pemphigus differently with rituximab. I am more likely to recommend rituximab as first-line therapy if a patient has severe oral or genital disease, as this can be very quality-of-life limiting. Furthermore, relapse assessment can be challen...

In pemphigus specifically, my approach to dosing rituximab is not typically dictated by clinical phenotype. Interestingly, while anti-desmoglein 1 antibody level reductions following rituximab have been correlated with improved treatment response when compared with desmoglein 3 antibody level change...